CURRENT OPINION IN PHARMACOLOGY

Scope & Guideline

Connecting Researchers to the Pulse of Pharmacology

Introduction

Welcome to the CURRENT OPINION IN PHARMACOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of CURRENT OPINION IN PHARMACOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1471-4892
PublisherELSEVIER SCI LTD
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 2001 to 2024
AbbreviationCURR OPIN PHARMACOL / Curr. Opin. Pharmacol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address125 London Wall, London EC2Y 5AS, ENGLAND

Aims and Scopes

CURRENT OPINION IN PHARMACOLOGY serves as a platform for the dissemination of cutting-edge research and reviews in the field of pharmacology, emphasizing therapeutic innovations, mechanistic insights, and translational applications. The journal aims to bridge the gap between basic research and clinical practice, providing insights into emerging therapies and pharmacological strategies.
  1. Therapeutic Innovations:
    The journal focuses on novel therapeutic strategies and advancements in drug development across various medical fields, including oncology, neurology, and pain management.
  2. Mechanistic Insights:
    Emphasizing the understanding of biochemical and molecular mechanisms underlying drug action and disease pathology, the journal publishes studies that elucidate the pharmacodynamics and pharmacokinetics of new and existing drugs.
  3. Translational Research:
    CURRENT OPINION IN PHARMACOLOGY highlights the translation of laboratory findings into clinical applications, showcasing studies that connect preclinical research with potential therapeutic outcomes.
  4. Disease-Specific Pharmacology:
    The journal addresses pharmacological approaches tailored to specific diseases, including autoimmune disorders, metabolic syndromes, and neurodegenerative conditions.
  5. Interdisciplinary Approaches:
    Encouraging collaboration across disciplines, the journal publishes research that integrates pharmacology with fields such as genetics, immunology, and systems biology to develop comprehensive therapeutic strategies.
CURRENT OPINION IN PHARMACOLOGY has identified several trending and emerging themes that reflect the journal's responsiveness to contemporary challenges in pharmacology and therapeutics. These themes highlight areas of increasing research focus and potential for future developments.
  1. Pain Management Innovations:
    Recent publications demonstrate a growing emphasis on innovative pain management strategies, including the exploration of novel targets such as TRP channels and the endocannabinoid system, as well as biased signaling in analgesics.
  2. Targeted Therapies in Cancer:
    There is a surge in research focusing on targeted therapies for cancer treatment, particularly those that leverage advancements in understanding DNA damage repair and tumor microenvironment interactions.
  3. Neuropharmacology Advances:
    Emerging studies on neuropharmacology, particularly regarding neurodegenerative diseases and mental health, reflect a trend towards developing therapies that address complex neurological pathways.
  4. Personalized Medicine and Pharmacogenomics:
    The journal is increasingly featuring articles on personalized medicine approaches, highlighting the importance of pharmacogenomics in tailoring treatments to individual patient profiles.
  5. Integration of AI and Computational Methods:
    The incorporation of artificial intelligence and computational modeling in drug discovery and pharmacology is gaining traction, signifying a trend towards data-driven approaches in therapeutic development.

Declining or Waning

As the field of pharmacology evolves, certain themes and research areas have shown a decline in prominence within CURRENT OPINION IN PHARMACOLOGY. This section highlights those aspects that are becoming less common in recent publications.
  1. Traditional Pharmacotherapy:
    There is a noticeable decline in papers focused on traditional pharmacotherapy approaches, as the field shifts towards more innovative and personalized medicine strategies that incorporate genetic and molecular insights.
  2. General Reviews without Novel Insights:
    The journal has seen a reduction in general review articles that do not contribute new insights or perspectives, with a preference for publications that offer novel findings or advanced methodologies.
  3. Single-Drug Focus Studies:
    Research focusing solely on the efficacy of single drugs without considering combination therapies or multidisciplinary approaches appears to be less frequent, reflecting a broader trend towards integrative treatment strategies.
  4. Overemphasis on Mechanistic Studies:
    While mechanistic studies remain important, there is a declining interest in purely mechanistic explorations without translational implications, as researchers and clinicians increasingly seek studies with direct clinical relevance.

Similar Journals

TRENDS IN PHARMACOLOGICAL SCIENCES

Bridging Knowledge and Practice in Pharmacological Sciences
Publisher: CELL PRESSISSN: 0165-6147Frequency: 12 issues/year

TRENDS IN PHARMACOLOGICAL SCIENCES, an esteemed journal published by CELL PRESS, is a leading platform in the field of pharmacology and toxicology, with an impressive history since its inception in 1979. With an impact factor that places it in the top quartile category (Q1) for both pharmacology and toxicology as of 2023, it is recognized for disseminating high-quality, peer-reviewed research that shapes the future of these disciplines. The journal is indexed with a robust standing in Scopus rankings, positioned at rank #2 in Toxicology and #6 in Pharmacology, both boasting an extraordinary percentile of 98. Researchers, professionals, and students benefit from its comprehensive coverage, which spans cutting-edge advancements, review articles, and significant trends in drug development and toxicity assessment. While the journal does not currently offer open access options, it remains a vital resource for the academic community, ensuring critical insights into the complexities of pharmacological sciences are readily available to enhance research and practice.

European Journal of Pharmacology

Advancing drug discovery through innovative research.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

DRUG DEVELOPMENT RESEARCH

Unveiling breakthroughs in drug development for a healthier tomorrow.
Publisher: WILEYISSN: 0272-4391Frequency: 8 issues/year

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

Drug Target Insights

Pioneering Open Access to Critical Pharmacological Research.
Publisher: ABOUTSCIENCE SRLISSN: 1177-3928Frequency: 1 issue/year

Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.

ACS Pharmacology & Translational Science

Driving breakthroughs from bench to bedside.
Publisher: AMER CHEMICAL SOCISSN: Frequency: 12 issues/year

ACS Pharmacology & Translational Science is a premier journal published by the American Chemical Society, dedicated to advancing knowledge in the fields of pharmacology and translational science. Operating since 2018, the journal has quickly established itself as a leader in its domain, holding a prestigious Q1 ranking in both Pharmacology and Medical Pharmacology for 2023. With a robust Scopus ranking, it currently occupies the 21st position out of 272 in Medical Pharmacology, reflecting its significant impact within the scientific community at the 92nd percentile. The journal provides an open-access platform for researchers to disseminate innovative findings and viewpoints that bridge the gap between drug discovery and clinical application. In an era where translational research is critical for the success of pharmacological advances, ACS Pharmacology & Translational Science serves as an essential resource for scientists, professionals, and students eager to explore cutting-edge developments in drug development and therapeutic strategies. The journal is based in the United States, with a commitment to fostering collaboration and knowledge sharing across borders.

ACTA PHARMACOLOGICA SINICA

Fostering Innovation in the Pharmaceutical Landscape
Publisher: NATURE PUBL GROUPISSN: 1671-4083Frequency: 12 issues/year

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

CLINICAL PHARMACOLOGY & THERAPEUTICS

Empowering healthcare through cutting-edge pharmacological research.
Publisher: WILEYISSN: 0009-9236Frequency: 6 issues/year

CLINICAL PHARMACOLOGY & THERAPEUTICS, published by WILEY, stands at the forefront of pharmacological research, serving as a pivotal resource for researchers, healthcare professionals, and students in the medical field. With its prestigious Q1 rating in both Pharmacology and Pharmacology (medical) categories, and ranking in the top 4% of journals in the field, it provides cutting-edge insights into drug therapy, pharmacokinetics, and innovative treatment strategies. The journal features a wide range of articles, from original research to comprehensive reviews, all aimed at advancing knowledge and clinical practice in pharmacology. With a publication history dating back to 1960 and continuing through 2024, its commitment to excellence is evident in its robust impact factor and high visibility in the academic community. For professionals striving to stay at the forefront of pharmacological advancements, CLINICAL PHARMACOLOGY & THERAPEUTICS remains an essential platform for disseminating and accessing vital research findings.

MEDICINAL RESEARCH REVIEWS

Pioneering Reviews that Shape the Future of Medicine
Publisher: WILEYISSN: 0198-6325Frequency: 6 issues/year

MEDICINAL RESEARCH REVIEWS, published by Wiley, is a leading journal in the fields of Drug Discovery, Molecular Medicine, and Pharmacology. With an impressive impact factor and esteemed standing in its category quartiles (Q1 in all three fields), this journal serves as a vital platform for the dissemination of cutting-edge research and reviews that drive innovation in therapeutic development and molecular health sciences. Since its inception in 1981, MEDICINAL RESEARCH REVIEWS has garnered a robust readership within the scientific community, underscored by its high rankings in Scopus – where it ranks #3 in Pharmacology and #2 in Drug Discovery, placing it within the top echelons of academic influence. Researchers, professionals, and students alike benefit from its rich content and comprehensive approaches to tackling complex medicinal challenges, making it an essential resource for those invested in advancing the frontiers of biomedical research.

INDIAN JOURNAL OF PHARMACOLOGY

Exploring the frontiers of pharmacology since 1978.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.

Recent Advances in Inflammation & Allergy Drug Discovery

Advancing drug discovery for a healthier tomorrow.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 2772-2708Frequency: 2 issues/year

Recent Advances in Inflammation & Allergy Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed open-access journal dedicated to the dynamic fields of drug discovery, immunology, and allergy. Since its inception in 2021, this journal has emerged as a crucial platform for disseminating groundbreaking research and innovative methodologies that drive forward our understanding of inflammatory processes and allergic diseases. With an ISSN of 2772-2708 and an E-ISSN of 2772-2716, it is currently indexed in various categories, boasting a Q3 ranking in Drug Discovery and Immunology & Allergy, and a Q1 ranking in Medicine (miscellaneous) for 2022. Operating from the United Arab Emirates, the journal aims to bridge the gap between laboratory research and clinical application, offering a comprehensive collection of articles that are accessible to a broad audience. Through its commitment to open access, it ensures that critical findings are widely available, fostering collaboration and innovation among researchers, practitioners, and students alike. Join the scholarly community engaged in this vital area of research and contribute to the ongoing advancements in inflammation and allergy therapeutics.